Jade Biosciences (JBIO) Convertible Debt (2024)
Jade Biosciences posted quarterly Convertible Debt of $107.6 million for Q4 2024.
Jade Biosciences (JBIO) has 1 years of Convertible Debt data on file, last reported at $107.6 million in Q4 2024.
- For the quarter ending Q4 2024, Convertible Debt changed N/A year-over-year to $107.6 million; the trailing twelve-month figure through Dec 2024 stood at $107.6 million (changed N/A YoY), and the FY2024 full-year result was $107.6 million, changed N/A from the prior year.
- Convertible Debt for Q4 2024 stood at $107.6 million.
- Across five years, Convertible Debt topped out at $107.6 million in Q4 2024 and bottomed at $107.6 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 107.60 Mn |